6ix — Find Your Next Investment

Discover investor relations events, company profiles, and investment opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Original text

Rate this translation

Your feedback will be used to help improve Google Translate

Latest Press Releases

Time	Headline
15m ago	Pacific Valley Bancorp Shows Continued Growth in Loans and Deposits and Improved Profitability in the First Quarter of 2026
16m ago	U-BX Technology Ltd. Announces Pricing of $4.55 Million Registered Direct Offering
16m ago	Company’s 3-for-1 Stock Split Cleared by FINRA for OTC Markets Trading
17m ago	L.B. Foster Company to Report First Quarter 2026 Results on May 4, 2026
17m ago	Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape \| DelveInsight

About

Inhibikase Therapeutics Inc (NASDAQ:IKT) — investor relations, events, news, and company updates on 6ix.

Latest News

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Financials

Revenue

$1

Market Cap

$237.66 M

EPS

-0.49

Community Chat

Ask AI